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Background: Elevated expression of erbB3 receptor has been reported to induce resistance to therapeutic agents,
including trastuzumab in erbB2-overexpressing breast cancer. Our recent studies indicate that erbB3 interacts with
both erbB2 and IGF-1 receptor to form a heterotrimeric complex in trastuzumab-resistant breast cancer cells. Herein,
we investigate the antitumor activity of MM-121/SAR256212, a fully human anti-erbB3 antibody (Ab), against two
erbB2-overexpressing breast cancer cell lines resistant to trastuzumab.
Methods: MTS-based proliferation assays were used to determine cell viability upon treatment of trastuzumab
and/or MM-121/SAR256212. Cell cycle progression was examined by flow cytometric analysis. Western blot analyses
were performed to determine the expression and activation of proteins. Tumor xenografts were established by
inoculation of the trastuzumab-resistant BT474-HR20 cells into nude mice. The tumor-bearing mice were treated with
trastuzumab and/or MM-121/SAR256212 via i.p injection to determine the Abs’ antitumor activity. Immunohistochemical
analyses were carried out to study the Abs’ inhibitory effects on tumor cell proliferation and induction of apoptosis
in vivo.
Results: MM-121 significantly enhanced trastuzumab-induced growth inhibition in two sensitive and two resistant
breast cancer cell lines. MM-121 in combination with trastuzumab resulted in a dramatic reduction of phosphorylated
erbB3 (P-erbB3) and Akt (P-Akt) in the in vitro studies. MM-121 combined with trastuzumab did not induce apoptosis in
the trastuzumab-resistant cell lines under our cell culture condition, rather induced cell cycle G1 arrest mainly associated
with the upregulation of p27kip1. Interestingly, in the tumor xenograft model established from the trastuzumab-resistant
cells, MM-121 in combination with trastuzumab as compared to either agent alone dramatically inhibited tumor growth
correlated with a significant reduction of Ki67 staining and increase of cleaved caspase-3 in the tumor tissues.
Conclusions: The combination of MM-121 and trastuzumab not only inhibits erbB2-overexpressing breast cancer cell
proliferation, but also promotes the otherwise trastuzumab-resistant cells undergoing apoptosis in an in vivo xenografts
model. Thus, MM-121 exhibits potent antitumor activity when combined with trastuzumab under the studied conditions.
Our data suggest that further studies regarding the suitability of MM-121 for treatment of breast cancer patients whose
tumors overexpress erbB2 and become resistant to trastuzumab may be warranted.
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Amplification and/or overexpression of erbB2 (or HER2/
neu) occur in approximately 25% of invasive breast cancer
and are significantly associated with a worse prognosis
for breast cancer patients [1-3]. As an erbB2-targeted
therapy, trastuzumab (also known as Herceptin, a huma-
nized monoclonal antibody (Ab) against erbB2) has been
approved by FDA and demonstrated significant activity in
the treatment of breast cancer patients with erbB2-overex-
pressing (erbB2+) tumors [4-6]; however, both primary
(de novo) and acquired resistances to trastuzumab are
common and currently represent a significant clinical
problem [7-9]. Thus, identification of novel therapeutic
strategies/agents to overcome trastuzumab resistance is
vital to improve the survival of breast cancer patients
whose tumors overexpress erbB2.
Studies on the underlying mechanisms suggest that
increased resistance to therapeutic agents is one of the
major mechanisms by which erbB2 contributes to breast
tumorigenesis [10]. Nonetheless, erbB2 does not act in
isolation. It often interacts with other receptor tyrosine
kinases (RTKs), such as erbB3, to activate the oncogenic
signaling, like PI-3K/Akt pathway, in breast cancers [11].
Co-expression of erbB3 and erbB2 is frequently observed
in breast cancers [12] and breast cancer cell lines [13], and
erbB3 plays an important role in breast cancer development
driven by erbB2 amplification/overexpression [14]. It
has been shown that erbB3 serves as a critical co-receptor
of erbB2, and its expression is a rate-limiting factor for
erbB2-induced breast cancer cell survival and proliferation
[14,15]. Unlike the widely studied erbB2 and EGFR in
human cancers, there has been relatively less emphasis
on erbB3 as a molecular target for cancer treatment. Cur-
rently used erbB2-targeted therapies in clinic can be di-
vided into two strategies: blocking Ab, such as trastuzumab
targeting erbB2; and tyrosine kinase inhibitor, such as
lapatinib against both EGFR and erbB2. For the erbB3
receptor, because of its lack of or low kinase activity
[16,17], targeting of erbB3 with a monoclonal Ab is the
only strategy currently under preclinical investigation
[18,19] and clinical studies in patients with advanced solid
tumors (http://www.clinicaltrials.gov). Recent studies have
also identified bispecific Abs dual-targeting of EGFR/erbB3
[20] or erbB2/erbB3 [21], that exhibit potent antitumor
activities in laboratory studies. In addition, the erbB3
inhibitors based on a novel biologic scaffold termed a
surrobody have been developed and show inhibitory effects
on tumor cell proliferation in vitro and in vivo [22]. MM-
121/SAR256212 is a fully human anti-erbB3 monoclonal
IgG2 Ab being co-developed by Merrimack Pharmaceuti-
cals and Sanofi. It inhibits ligand-induced dimerization
of erbB3 and erbB2 and subsequently inactivates the
downstream signaling. MM-121 has been demonstrated
to exert antitumor activity in preclinical models of humancancers, including erbB2+ breast cancer [18,19]. However,
whether MM-121 holds potential to overcome trastuzumab
resistance and enhance trastuzumab-mediated growth
inhibition in erbB2+ breast cancer cells remains unclear.
Mechanistic studies implicate the function of erbB3 as
a major cause of treatment failure in human cancers [23].
In the last several years, our laboratory has focused on
studying the biologic features of erbB3 receptor in erbB2+
breast cancer, and published a serious of articles indicating
that activation of erbB3 signaling, mainly through PI-3K/
Akt pathway, is essential for erbB2-induced therapeutic
resistance to tamoxifen [24], paclitaxel [25], and trastuzu-
mab [26]. Interestingly, activation of the PI-3K/Akt sig-
naling has been identified as the major determinant of
trastuzumab resistance [27]. Indeed, our recent studies
with the unique trastuzumab-resistant breast cancer model
demonstrate that the erbB3 receptor interacts with
both erbB2 and the insulin-like growth factor-1 receptor
(IGF-1R) to form a heterotrimeric complex, which mainly
activates the PI-3K/Akt signaling and Src kinase and
subsequently leads to trastuzumab resistance [26]. We
hypothesized that the anti-erbB3 Ab MM-121 can over-
come trastuzumab resistance and enhance the efficacy of
trastuzumab against erbB2+ breast cancer. In the current
study, we investigated the potential of MM-121 in com-
bination with trastuzumab on inducing growth inhibition
and/or apoptosis in two trastuzumab-sensitive and two
trastuzumab-resistant breast cancer cell lines in vitro,
and explored their inhibitory effects on the growth of
tumor xenografts-derived from a trastuzumab-resistant
breast cancer cell line in vivo.
Results
MM-121 significantly enhances the inhibitory effects of
trastuzumab on erbB2+ breast cancer cell lines associated
with the inactivation of erbB3/PI-3K/Akt signaling
To explore whether the anti-erbB3 Ab MM-121 may en-
hance the activity of trastuzumab against erbB2+ breast
cancers, we investigated the combinatorial effects of MM-
121 and trastuzumab on erbB3 signaling and cell prolifer-
ation in two erbB2+ breast cancer cell lines (SKBR3 and
BT474). The cells were treated with either MM-121 or
trastuzumab alone, or their combinations for 24 hrs, and
then subjected to western blot analysis. We found that
treatment with trastuzumab mainly reduced the levels of
phosphorylated erbB3 (P-erbB3) and phosphorylated Akt
(P-Akt) in both SKBR3 and BT474 cell lines, whereas
MM-121 had no obvious effects on P-erbB3 and P-Akt.
However, the combinations of MM-121 and trastuzumab
more potently decreased P-erbB3 and P-Akt as compared
to trastuzumab alone in SKBR3 cells and to a less extend in
BT474 cells (Figure 1A). Neither MM-121 or trastuzumab
alone, nor their combinations had significant effects on
erbB2 kinase activity, MAPK signaling, and the expression
Figure 1 MM-121 enhances trastuzumab-mediated inactivation of Akt and growth inhibition in two erbB2+ breast cancer cell lines. A,
SKBR3 and BT474 breast cancer cells were untreated or treated with either trastuzumab or MM-121 alone, or their combinations for 24 hrs. Cells
were collected and subjected to western blot analyses of P-erbB2, erbB2, P-erbB3, erbB3, P-Akt, Akt, P-MAPK, MAPK, or β-actin. B, SKBR3 and
BT474 cells were plated onto 96-well plates and incubated at 37°C with 5% CO2. After 24 hrs, the culture medium was replaced with 0.1 ml fresh
medium containing 0.5% FBS or the same medium containing the indicated concentrations of trastuzumab in the absence (Trast) or presence
(Trast + MM-121) of MM-121 (10 μg/ml) for another 72 hrs. The percentages of surviving cells from each cell line relative to controls, defined as
100% survival, were determined by reduction of MTS. Bars, SD. Data show a representative of three independent experiments.
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http://www.molecular-cancer.com/content/12/1/134of erbB2/erbB3 receptors (Figure 1A). Cell growth assays
revealed that trastuzumab inhibited proliferation of SKBR3
and BT474 cell lines in a dose-dependent manner, con-
sistent with our previous findings [26]. The addition ofMM-121 significantly enhanced trastuzumab-mediated
growth inhibition in both SKBR3 and BT474 cell lines
(Figure 1B). Since activation of the erbB3 signaling plays
an important role in the development of trastuzumab
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http://www.molecular-cancer.com/content/12/1/134resistance [26], we next studied whether MM-121 might
overcome the resistance and enhance trastuzumab-
mediated growth inhibition in two otherwise resistant
breast cancer cell lines. SKBR3-pool2 and BT474-HR20 are
trastuzumab-resistant sublines-derived from SKBR3 and
BT474 cell lines, respectively [26,28]. While SKBR3-pool2
cells were kindly provided by Dr. Francisco Esteva at MD
Anderson Cancer Center [28,29], the BT474-HR20 sub-
line was developed by our laboratory through conti-
nuously exposing BT474 cells to trastuzumab in culture
for 4 months [26,30]. Indeed, both SKBR3-pool2 and
BT474-HR20 cells maintained their resistant phenotype to
trastuzumab treatment as compared to their sensitive
counterparts (Figure 2A vs Figure 1B). However, the pre-
sence of MM-121 significantly enhanced trastuzumab-
mediated growth inhibition in both SKBR3-pool2 and
BT474-HR20 cell lines (Figure 2A). Further studies on
erbB3 activation and the downstream signaling showed
that while either MM-121 or trastuzumab alone induced a
clear reduction of P-erbB3 and P-Akt and had no signifi-
cant effects on P-erbB2 and P-MAPK, the combinations of
MM-121 and trastuzumab dramatically reduced P-erbB3
and P-Akt in both SKBR3-pool2 and BT474-HR20 cell
lines (Figure 2B). Taken together, our data indicate that the
erbB3 blocking Ab MM-121 significantly enhances
trastuzumab-induced growth inhibition in two erbB2+
breast cancer cell lines and exhibits potential to over-
come trastuzumab resistance mainly through inactivation
of the erbB3/PI-3K/Akt signaling.
MM-121 in combination with trastuzumab induces cell
cycle G1 arrest in both trastuzumab-sensitive
and -resistant breast cancer cell lines
To study the molecular mechanism by which MM-121
overcomes trastuzumab resistance and enhances trastuzu-
mab’s efficacy on inhibition of cell proliferation and/or sur-
vival in the studied cell lines, we considered the mechanism
of action of trastuzumab inducing cell cycle G1 arrest
[4,31,32] and thus investigated the combinatorial effects
of MM-121 and trastuzumab on the expression levels of
several critical molecules participating in G1-S transition
and cell cycle progression in erbB2+ breast cancer cell
lines. In the trastuzumab-sensitive cells, trastuzumab alone
induced a minor reduction of E2F-1 and a slight increase
of p27kip1 in SKBR3 cells, and it only upregulated p27kip1
in BT474 cells (Figure 3A). MM-121 alone did not alter
the expression levels of E2F-1 and p27kip1 in either cell
lines. However, the combinations of trastuzumab and
MM-121 clearly increased the levels of p27kip1 in both cell
lines and led to a minor reduction of E2F-1 in SKBR3 cells
(Figure 3A). The expression levels of cyclin D1 were not
significantly changed upon treatment with trastuzumab
and/or MM-121. Flow cytometry analysis of cell cycle
distribution showed that trastuzumab alone increased thecells at G1 phase in both cell lines, whereas MM-121 en-
hanced G1 population only in SKBR3 cells. Importantly,
MM-121 in combination with trastuzumab more dra-
matically increased the percentage cells at G1 phase
and decreased the cells at S phase in both cell lines
(Figure 3B), suggesting a further induction of G1 arrest. In
the trastuzumab-resistant cells, the expression levels of
p27kip1 were slightly increased upon treatment with either
trastuzumab or MM-121 alone, whereas the combinations
of MM-121 and trastuzumab not only upregulated p27kip1
in both SKBR3-pool2 and BT474-HR20 cell lines, but also
decreased E2F-1 in SKBR3-pool2 cells (Figure 4A). Fur-
thermore, cell cycle analysis confirmed that the combina-
tions of MM-121 and trastuzumab exhibited more potent
activity than either agent alone to increase the G1 popula-
tion and decrease the cells at S phase (Figure 4B). MM-121
and/or trastuzumab had no significant effect on G2-M
transition in both trastuzumab-sensitive and -resistant cells
(Figures 3B & 4B). While Figures 3B and 4B show the rep-
resentative data, statistical analyses of G1 population from
multiple cell cycle assays were also performed, and we
found that the combinations of MM-121 and trastuzumab
as compared to trastuzumab alone significantly increased
G1 population in SKBR3, SKBR3-pool2, and BT474-HR20
cells (Additional file 1: Figure S1). Additional studies on in-
duction of apoptosis showed that MM-121 and/or trastu-
zumab did not induce apoptosis in our cell culture
condition (data not shown). Collectively, our studies sug-
gest that the combinations of MM-121 and trastuzumab
inhibited proliferation of both trastuzumab-sensitive and
trastuzumab-resistant breast cancer cells mainly through
cell cycle G1 arrest, which was correlated with the upregu-
lation of p27kip1 and sometimes a concomitant downregu-
lation of E2F-1.
The combinations of MM-121 and trastuzumab significantly
inhibit growth of tumor xenografts-established from a
trastuzumab-resistant breast cancer cell line in nude mice
To further explore whether MM-121 holds potential to
overcome trastuzumab resistance in an in vivo model for
breast cancer treatment, we took advantage of the tumor
xenografts model established from the trastuzumab-
resistant breast cancer cell line BT474-HR20. There is a
general concern that erbB2+ breast cancer cell lines are
difficult to form spontaneous xenografts in athymic nu/
nu mice [33], and it is not known whether the BT474-
HR20 cells would maintain their trastuzumab-resistant
phenotype in vivo. We first compared the ability of
trastuzumab-sensitive and -resistant cells to form tu-
mors in nude mice. We found that the BT474-HR20
cells formed tumors with a shorter latency than BT474
cells, and the tumors established from the resistant cells
grew significantly faster than those from the parental
cells (Additional file 2: Figure S2A), suggesting the
Figure 2 MM-121 significantly enhances trastuzumab-induced growth inhibition in two otherwise resistant cell lines correlated with
inactivation of the erbB3/PI-3K/Akt signaling. A, SKBR3-pool2 and BT474-HR20 cells were plated onto 96-well plates and incubated at 37°C
with 5% CO2. After 24 hrs, the culture medium was replaced with 0.1 ml fresh medium containing 0.5% FBS or the same medium containing
the indicated concentrations of trastuzumab in the absence (Trast) or presence (Trast + MM-121) of MM-121 (10 μg/ml) for another 72 hrs. The
percentages of surviving cells from each cell line relative to controls, defined as 100% survival, were determined by reduction of MTS. Bars, SD.
Data show a representative of three independent experiments. B, SKBR3-pool2 and BT474-HR20 cells were untreated or treated with either
trastuzumab or MM-121 alone, or their combinations for 24 or 48 hrs. Cells were collected and subjected to western blot analyses with the
indicated antibodies.
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Figure 3 The addition of MM-121 enhances trastuzumab-induced cell cycle G1 arrest in erbB2+ breast cancer cell lines. SKBR3 and
BT474 cells were untreated or treated with either trastuzumab or MM-121 alone, or their combinations for 24 hrs. A, Half of the cells were
collected and subjected to western blot analyses with specific antibodies directed against E2F-1, Cyclin D1, p27kip1, or β-actin. The densitometry
analyses of E2F-1, Cyclin D1, and p27kip1 signals were shown underneath, and the arbitrary numbers indicate the intensities of each sample
relative to controls, defined as 1.0. B & C, The other half of the cells were collected for analysis of cell cycle distributions by flow cytometry as
described in the Materials and Methods. Data show a representative of three independent experiments.
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tantly, the tumors-derived from BT474-HR20 cells
were still growing under the treatment of trastuzumab
(Additional file 2: Figure S2B), whereas the tumors-
derived from BT474 cells were eliminated after three
doses of trastuzumab (Additional file 2: Figure S2C).
These data suggest that although BT474-HR20 cells
were obtained in in vitro cell culture condition, they
still maintained the trastuzumab-resistant phenotype
in vivo. We next performed the following in vivo experi-
ments with Ab treatment. When BT474-HR20 tumor
volumes reached ~65 mm3, the nude mice were treated
with either PBS (control), or MM-121 or trastuzumab
alone, or the combinations of MM-121 and trastuzu-
mab. Treatment with trastuzumab alone resulted in a
minor and statistically insignificant inhibition (Figure 5A).
It appeared that MM-121 alone had a stimulatory effect
on the growth of BT474-HR20 tumor xenograft, although
the differences were statistically insignificant. However,
this phenomenon was not observed consistently. In our
recent publication, MM-121 alone had neither positive
nor negative effect on in vivo tumor growth of BT474-
HR20 cells . More importantly, the combinations of MM-
121 and trastuzumab significantly inhibited tumor growth
of BT474-HR20 cells (Figure 5A). After 6-time treatments,
the remaining tumors from the combinatorial treatment
were very small. We did observe tumor regression in the
time frame of our experiments. Histology and immunohis-
tochemistry (IHC) assays revealed that treatment with
MM-121 or trastuzumab alone did not alter tumor cell
morphology and the expression of erbB2/erbB3 receptors
(Figure 5B). In contrast, the combinatorial treatment re-
sulted in much less tumor cells remaining, lost tumor
architecture, and increased fibroblast cells in the tissues.
Nonetheless, the remaining tumor cells maintained a simi-
lar expression levels of both erbB2 and erbB3 receptors
(Figure 5B), which was consistent with the results of our
cell culture studies (Figure 2B).
MM-121 enhances trastuzumab’s antitumor activity
against the otherwise resistant breast cancer cells via
induction of both cell growth inhibition and apoptosis
in vivo
While our cell culture studies discovered that MM-121 in
combination with trastuzumab inhibited proliferation of
SKBR3-pool2 and BT474-HR20 cell lines (Figure 2A)without induction of apoptosis (data not shown), we
wondered whether the combinations of MM-121 and tras-
tuzumab would have similar effects on the trastuzumab-
resistant cells in vivo. By utilizing the tumor tissues
obtained from the BT474-HR20 xenograft animal studies
described above, we then performed IHC studies on the
classic cell proliferative marker Ki67 and cleaved caspase-3,
an indicative of cells undergoing apoptosis. The mice
treated with MM-121 or trastuzumab exhibited a minor
reduction in the number of tumor cells with positive stai-
ning of Ki67 as compared to the control mice (Figure 6A).
Neither MM-121 nor trastuzumab induced caspase-3
cleavage in the tumor tissues. However, the mice treated
with both MM-121 and trastuzumab showed a dramatic
reduction in the number of tumor cells with positive stain-
ing of Ki67 and a significant increase of the tumor cells
with cleaved caspase-3 (Figure 6 and Additional file 3:
Figure S3). These data indicate that MM-121 enhances
trastuzumab’s antitumor activity against the otherwise re-
sistant breast cancer cells via induction of both cell growth
inhibition and apoptosis in this in vivo model.
Discussion
As a unique member of the erbB receptor family, erbB3
has long been considered an inactive “pseudokinase”
[16,34]. A recent study suggests that erbB3 has weak
kinase activity that can trans-autophosphorylate its intra-
cellular region [17]. In order to fully transduce cell signa-
ling, however, erbB3 has to be phosphorylated by its
interactive partners, of these, erbB2 is the most important
one [35]. It has been well-documented that activation of
the erbB3 signaling plays a pivotal role in the development
of erbB2+ breast cancer [14,15], castration-resistant
prostate cancer [36], platinum resistant/refractory ovarian
cancer [37,38], and etc. Nonetheless, no erbB3-targeted
therapy has been approved for cancer treatment. MM-121
is an erbB3 blocking Ab that is being actively investigated,
mainly in combination with chemotherapy, in clinical
trials of cancer patients with solid tumors, such as
advanced non-small cell lung cancer, colorectal cancer,
squamous cell head & neck cancer, platinum resistant/
refractory ovarian cancer (http://www.clinicaltrials.gov/
ct2/results?term=mm-121). In breast cancer, MM-121’s
therapeutic potential is being tested in patients with ER
and/or PR positive and erbB2 negative breast cancers in
combination with the aromatase inhibitor exemestane,
Figure 4 (See legend on next page.)
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Figure 4 The combination of MM-121 and trastuzumab induces cell cycle G1 arrest mainly associated with induction of p27kip1 in two
trastuzumab-resistant cell lines. SKBR3-pool2 and BT474-HR20 cells were untreated or treated with either trastuzumab or MM-121 alone, or
their combinations for 24 hrs. A, Half of the cells were collected and subjected to western blot analyses with specific antibodies directed against
E2F-1, Cyclin D1, p27kip1, or β-actin. The densitometry analyses of E2F-1, Cyclin D1, and p27kip1 signals were shown underneath, and the arbitrary
numbers indicate the intensities of each sample relative to controls, defined as 1.0. B & C, The other half of the cells were collected for cell cycle
analysis. Data show a representative of three independent experiments.
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breast cancers in combination with paclitaxel. To date, no
clinical study has been initiated to test MM-121’s activity
in breast cancer patients with erbB2+ tumors, particularly
those become resistant to trastuzumab. Here, we demon-
strated that MM-121 significantly enhanced trastuzumab-
mediated growth inhibition in two sensitive and two
resistant breast cancer cell lines. More importantly, the
studies using a specific tumor xenograft model further
proved that MM-121 exerted potent activity to overcome
trastuzumab resistance in that in vivo model. Thus, our
data provide a strong basis to explore the therapeutic
potential of MM-121 in combination with trastuzumab in
erbB2+ breast cancer patients resistant to trastuzumab.
Our previous studies showed that the mechanism of
trastuzumab resistance in SKBR3-pool2 and BT474-HR20
cells was due to the formation of a heterotrimeric complex
consisting of erbB2, erbB3, and IGF-1R [26]. We disco-
vered that the expression of both erbB3 and IGF-1R was
critical for maintaining trastuzumab-resistant phenotype,
since specific knockdown of either erbB3 or IGF-1R sig-
nificantly abrogated the resistance in SKBR3-pool2 and
BT474-HR20 cells [26]. The data presented here indicated
that inhibiting erbB3, but retaining its expression, also re-
sensitized the resistant cells to the treatment of trastu-
zumab in our in vitro (Figure 2) and in vivo (Figure 5)
models. It is not clear, however, whether inactivation of
erbB3 by MM-121 overcomes trastuzumab resistance
via disrupting the heterotrimerization of erbB2/erbB3/
IGF-1R. At this moment, the molecular basis of this het-
erotrimerization remains unknown. We speculate that
long-term exposure of SKBR3 or BT474 cells to trastuzu-
mab may induce expression of the ligands for erbB3
(heregulin, HRG) and IGF-1R (IGF-I and/or IGF-II),
which could subsequently recruit all three RTKs together
to form the unique heterotrimeric complex. Since MM-
121 inhibits ligand-induced dimerization between erbB3
and erbB2 [18,19], it may also interfere with the heterotri-
meric complex consisting of erbB2, erbB3, and IGF-1R in
SKBR3-pool2 and BT474-HR20 cells and thus overcome
the resistance. However, detailed studies are warranted to
test this hypothesis.
The combinations of MM-121 and trastuzumab inhi-
bited proliferation of two sensitive and two resistant
breast cancer cell lines in vitro; however, they induced
both growth inhibition and apoptosis in vivo. This cellkilling effects may be attributed to the enhanced antibody-
dependent cell-mediated cytotoxicity (ADCC) by natural
killer (NK) cells. Abundant evidence demonstrates that
one of the major mechanisms of action of trastuzumab is
through its IgG1 humanized Fc portion to activate ADCC
via host’s innate immune system [32]. In addition, cellular
adaptive immune response also plays an important role in
the clinical efficacy of trastuzumab [39]. Novel strategies
that enhance ADCC effectors, such as NK cells, are
sought to improve trastuzumab efficacy. A recent study
reported exciting data indicating that stimulation of NK
cells with a CD137-specific Ab significantly enhanced
trastuzumab-mediated cell killing in both sensitive and
resistant cell lines in vitro and in vivo [40]. In our case,
although MM-121 itself cannot trigger ADCC, because of
its IgG2 isotype [41], it is possible that inactivation of erbB3
with MM-121 may increase trastuzumab’s binding
efficiency to the tumor xenografts-established from
BT474-HR20 cells, and subsequently enhance trastuzu-
mab-mediated ADCC.
Activation of erbB3 generally signals through PI-3K/
Akt, MEK/MAPK, Jak/Stat pathways, and Src kinase to
modulate many downstream regulators that play a pivotal
role in maintaining malignant phenotype, including cell
survival, resistance, angiogenesis, and invasion [16,42].
Our data showed that treatment of certain erbB2+ breast
cancer cell lines with MM-121 resulted in a dramatic in-
hibition on PI-3K/Akt signaling, the major determinant of
trastuzumab resistance in breast cancer [27]. However, it
is not known whether MM-121 may potentially abrogate
resistance to lapatinib, another erbB2-targeted therapy to
treat metastatic breast cancer that has progressed after
trastuzumab-based therapy [43]. Lapatinib and trastuzu-
mab may not share common mechanism of resistance, as
lapatinib has activity in trastuzumab-resistant breast
cancer [44-47]. Some studies show that lapatinib exerts
antitumor activity in a PTEN independent manner [48],
whereas others report that loss of PTEN and the resulting
activation of PI-3K/Akt signaling lead to lapatinib resis-
tance [49]. Thus, it will be very interesting, and may have
clinical implications, to study if the combinations of MM-
121 and lapatinib may synergistically or additively induce
growth inhibition and/or apoptosis in BT474-HR20 and
SKBR3-pool2 cells. In addition, activation of the erbB2/
erbB3/PI-3K/Akt signaling also results in resistance to
hormonal therapy [50] and chemotherapy [51] in breast
Figure 5 (See legend on next page.)
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Figure 5 MM-121 in combination with trastuzumab significantly inhibits in vivo growth of tumor xenografts established from
BT474-HR20 trastuzumab-resistant breast cancer cells. BT474-HR20 cells were s.c. injected into nude mice to establish tumor xenografts. The
tumor-bearing mice (n = 5) received i.p. injections of PBS, trastuzumab, MM-121, or trastuzumab plus MM-121 as described in the Materials and
Methods. After 6 treatments, the mice were euthanized at day 36 post injection of tumor cells, and all tumors were excised for histology and IHC
analysis. A, The graphs show the tumor growth curves. Bars, SD. The combinations of MM-121 and trastuzumab significantly inhibited tumor
growth as compared to control or single Ab treatment. B, Data show the representative tumors with hematoxylin and eosin (H&E) staining and
IHC analysis of erbB2 and erbB3. The residual tumor cells obtained from combinatorial treatments retained similar expression levels of erbB2/
erbB3 receptors on the cell membrane.
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http://www.molecular-cancer.com/content/12/1/134cancer treatment. We have reported that elevated expres-
sion of erbB3 confers paclitaxel resistance in erbB2+
breast cancer cells via a PI-3K/Akt-dependent mechanism
[25]. Because MM-121 mainly inhibits activation of erbB3
and Akt (Figures 1 & 2), it is conceivable to hypothesize
that MM-121 may abrogate erbB3 signaling-mediated re-
sistance to paclitaxel as well. Indeed, we have discovered
that MM-121 is able to overcome paclitaxel resistance and
enhance paclitaxel-induced apoptosis in the otherwise re-
sistant breast cancer cell lines. The manuscript containing
those data is submitted separately.
Conclusions
MM-121 significantly enhances trastuzumab-induced
growth inhibition in erbB2+ breast cancer cell lines.
MM-121 is active to overcome trastuzumab resistance
in the studied in vitro and in vivo models. When com-
bined with trastuzumab, MM-121 mainly inhibits proli-
feration, without induction of apoptosis, via cell cycle
G1 arrest in vitro. However, their combinatorial in vivo
antitumor activity against the trastuzumab-resistant breast
cancer cells is attributed to induction of both growth
inhibition and apoptosis. Our data support further studies
to explore the therapeutic potential of MM-121 in
combination with trastuzumab in breast cancer patients




MM-121 was kindly provided by Merrimack Pharmaceuti-
cals, Inc. (Cambridge, MA). Trastuzumab (Herceptin®,
Genentech, South San Francisco, CA) was obtained from
University of Colorado Hospital pharmacy. Antibodies
used for western blots were as follows: erbB2 (EMD
Chemicals, Inc., Gibbstown, NJ); erbB3 and P-erbB2
(Tyr1248) (LabVision Corp., Fremont, CA); P-erbB3
(Tyr1289), P-MAPK (Thr202/Tyr204), MAPK, P-Akt
(Ser473), and Akt (Cell Signaling Technology, Inc.,
Beverly, MA); Cyclin D1 (M-20), E2F1 (KH95), and
p27kip1 (F-8) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA); and β-actin (Sigma Co., St. Louis, MO). All other
reagents were purchased from Sigma unless otherwise
specified.Cells and cell culture
Human breast cancer cell lines SKBR3 and BT474 were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA). The trastuzumab-resistant sub-
lines SKBR3-pool2 and BT474-HR20, derived from
SKBR3 and BT474, respectively, were described pre-
viously [26]. All cell lines were maintained in DMEM/
F-12 (1:1) medium (Sigma) containing 10% fetal bovine
serum (Sigma), and cultured in a 37°C humidified
atmosphere containing 95% air and 5% CO2 and split
twice a week.
Cell proliferation assay
The CellTiter96 AQ nonradioactive cell proliferation kit
(Thermo Fisher Scientific Inc., Waltham, MA) was used
to determine cell viability as previously described [25,26].
Briefly, cells were plated onto 96-well plates for 24 h, and
then grown in either DMEM/F12 medium with 0.5% FBS
as control, or the same medium containing different
concentrations of trastuzumab in the presence or absence
of MM-121, and then incubated for another 72 h. After
reading all wells at 490 nm with a microplate reader, the
percentages of surviving cells from each group relative to
controls, defined as 100% survival, were determined by
reduction of MTS.
Cell cycle analysis
Flow cytometric assays were performed as described previ-
ously [52] to define the cell cycle distribution. In brief,
cells grown in culture dishes were harvested by trypsini-
zation and fixed with 70% ethanol. Cells were stained for
total DNA content with a solution containing 50 μg/ml
propidium iodide and 100 μg/ml RNase I in PBS for
30 min at 37°C. Cell cycle distribution was analyzed at the
Flow Cytometry Core Facility of University of Colorado
Cancer Center with a FACScan flow cytometer (BD Bio-
sciences, San Jose, CA).
Western blot analysis
Protein expression levels were determined by western
blot analysis as described previously [26,30,52]. Equal
amounts of total cell lysates were boiled in Laemmli
SDS-sample buffer, resolved by SDS-PAGE, transferred
to nitrocellulose membrane (Bio-Rad Laboratories,
Figure 6 (See legend on next page.)
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Figure 6 The combination of MM-121 and trastuzumab significantly inhibits proliferation and induces apoptosis of trastuzumab-resistant
BT474-HR20 breast cancer cells in vivo. The tumors obtained from the animal studies described above were evaluated by IHC analysis of Ki67
and cleaved caspase-3. A, Data show the representative images of the immunostaining of Ki67 and cleaved caspase-3 (Cleaved Casp-3). B, The
IHC slides were observed by two independent personnel. The tumor cells with positive staining of Ki67 or cleaved caspase-3 were counted from
three randomly selected areas in each slide. The three areas were first identified by scanning the entire slide at ×10 magnification, and then the
positive staining cells were counted at ×20 magnification using an Olympus BX40 Microscope. The bar graphs show the average of positive
staining cells in each field. Bars, SD. The combinatorial treated mice had significantly fewer cells stained positive for Ki67 and more cells stained
positive for cleaved caspase-3 than control mice or single Ab treated mice, P < 0.008 and P < 0.05, respectively.
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http://www.molecular-cancer.com/content/12/1/134Hercules, CA), and probed with the primary antibodies
described in the figure legends. After the blots were
incubated with horseradish peroxidase-labeled secondary
antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA), the signals were detected using the enhanced
chemiluminescence reagents (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ).
Immunohistochemistry
Five micron thick paraffin sections were deparaffinized,
antigens unmasked and immunohistochemically stained
for Ki67 (Thermo Fisher Scientific; rabbit monoclonal
SP6; cat# RM-9106-SO; dilution 1:500 in TBST + 1%
BSA w/v), cleaved Caspase-3 (Cell Signaling Technology;
rabbit polyclonal; cat#: 9661, 1:1000 in TBST + 1% BSA
w/v), erbB2 (EMD Chemicals; mouse monoclonal 96G;
cat#OP14T; dilution 1:500 in TBST + 1% BSA w/v), and
erbB3 (Spring Bioscience, Pleasanton, CA; rabbit mono-
clonal SP71; cat# M3710; dilution 1:200 in TBST + 1%
BSA w/v). The specificity of all antibodies has been con-
firmed by both positive and negative controls. For erbB2
and erbB3, SKBR3 cells were used as a positive control.
For Ki67 and cleaved caspase-3, the human tonsil tissues
were used a positive control. All the negative controls
were performed with the same cells/tissues without
addition of the primary antibodies.
Ki67 and cleaved caspase-3 antigens were revealed in
pH 9.5 BORG solution (Biocare Medical, Concord, CA)
for 5 min at 125°C (22 psi; Decloaking chamber, Biocare).
ErbB2 required modest retrieval in 10 mmol/L sodium
citrate for 5 min at 125°C in the Decloaking chamber.
ErbB3 required retrieval in Cell Conditioner 1 (standard
retrieval time, Ventana). Immunodetection of Ki67,
cleaved Caspase-3 and erbB2 was performed on the
NexES stainer (Ventana Medical Systems, Tucson, AZ)
at an operating temperature of 37°C. Ki67 and cleaved
caspase-3 antibodies were incubated for 32 min and de-
tected with a modified I-VIEW DAB (Ventana) detec-
tion kit. The I-VIEW secondary antibody and enzyme
were replaced with a species specific secondary antibody
(biotinylated goat anti-rabbit; 1:75; cat# 111-065-144;
Jackson ImmunoResearch; 8 min) and streptavidin-
horseradish (SA-HRP; 1:50; cat# SA-5004; DAKO Cyto-
mation, Carpinteria, CA; 8 min). ErbB2 was incubatedfor 32 min and detected with the standard I-VIEW detec-
tion. ErbB3 was incubated for 32 min and detected with a
modified I-VIEW DAB kit in which the secondary anti-
body was replaced with Rabbit ImmPress (Vector Labs;
Burlingame, CA; cat# MP-7401; 8 minutes at 37°C) and
enzyme was replaced with Rabbit ImmPress (Diluted 1:1
in PBS pH 7.6; 8 minutes at 37°C). Sections were sequen-
tially blocked for 10 min in 3% hydrogen peroxide (v/v)
and 30 min in Rodent Block M (Biocare, cat# RBM961),
followed by primary antibody incubation for 30 min and
30 min in polymer. Antibody complexes were visualized
with IP Flex DAB (Biocare; cat# IPK5010 G80; 4.5%). All
sections were counterstained in Mayer’s hematoxylin for
2 min, nuclei blued in 1% ammonium hydroxide (v/v),
dehydrated in graded alcohols, cleared in xylene and co-
verglass mounted using synthetic resin.
Tumor xenograft model
Athymic nu/nu mice (Harlan Laboratories, Inc.,
Indianapolis, IN) were maintained in accordance with the
Institutional Animal Care and Use Committee (IACUC)
procedures and guidelines. Eight ×106 BT474-HR20 cells
were suspended in 100 μL of PBS, mixed with 50%
Matrigel (BD Biosciences) and injected subcutaneously
(S.C.) into the flanks of 5-week-old female mice. Tumor
formation was assessed by palpation and measured with
fine calipers three times a week. Tumor volume was
calculated by the formula: volume = (length × width2)/2,
where length was the longest axis and width the measure-
ment at a right angle to the length, and followed by sta-
tistical analysis as we described previously [52]. When
tumors reach ~65 mm3, mice were randomly assigned to
four groups (n = 5): 1) control group-mice received intra-
peritoneally (i.p) injection of 100 μl PBS only; 2) mice
received i.p. injection of trastuzumab (10 mg/kg) in 100 μl
PBS twice a week; 3) mice received i.p. injection of
MM-121 (10 mg/kg) in 100 μl PBS twice a week; 4) mice
received i.p. injection of trastuzumab (10 mg/kg) and MM-
121 (10 mg/kg) in 100 μl PBS twice a week. The animals’
health status was monitored daily for weight loss or for
signs of altered motor while in their cages. At the end of
study, mice were euthanized according to approved IACUC
protocol. Tumors from all animals were excised and em-
bedded in paraffin for immunohistochemical analyses.
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Statistical analyses of the experimental data were per-
formed using either a two-sided t test or ANOVA for
each time point followed by post-hoc testing between
groups. Significance was set at a P value of <0.05. All
statistical analyses were conducted with the software
StatView v5.1 from SAS Institute Inc., Cary, NC.Additional files
Additional file 1: Figure S1. Combinations of trastuzumab and MM-121
significantly induced cell cycle G1 arrest in both trastuzumab-sensitive and
-resistant breast cancer cells. SKBR3, BT474, SKBR3-pool2, or BT474-HR20 cells
were untreated or treated with either trastuzumab (20 μg/ml) or MM-121
(10 μg/ml) alone, or their combinations for 24 hrs. All the cells were
collected for analysis of cell cycle distributions by flow cytometry as
described in the Methods. The bar graphs show the percentages of the cells
at G1 phase for each sample relative to controls, defined as 100%. A, The
combinations of trastuzumab and MM-121 as compared to trastuzumab
significantly induced G1 arrest in SKBR3 cells. There was no significant
difference between these two treatments in BT474 cells, which was very
sensitive to the treatment of trastuzumab alone. B, The combinations of
trastuzumab and MM-121 as compared to trastuzumab significantly induced
G1 arrest in both SKBR3-pool2 and BT474-HR20 cells. Bars, SD. Statistical
analyses were performed using data from three independent experiments.
Additional file 2: Figure S2. Trastuzumab-resistant breast cancer cells
show significant growth advantage as compared to their sensitive
counterpart and retain their resistant phenotype in vivo. A, BT474 or
BT474-HR20 cells were injected s.c into the flanks of 5-week-old female
nude mice. Mice were checked for tumor formation three times per week.
Tumor volume was calculated by the formula: volume = (length × width2)/2,
and expressed as cubic millimeters. B & C, When tumor volumes
reached ~65 mm3, the animals were treated with either control (PBS) or
trastuzumab (20 mg/kg) four times. Tumors-derived from BT474-HR20
cells were still growing even in the presence of trastuzumab (B),
whereas the tumors-derived from BT474 cells were no longer detectable
after three doses of trastuzumab (C). Tumor volume was expressed as
cubic millimeters (mean ± SE; n = 5/group).
Additional file 3: Figure S3. Combinations of trastuzumab and
MM-121 significantly increase the percentage of positive-staining cells
with cleaved caspase-3 in vivo. The tumor IHC slides were observed by
two independent personnel. The tumor cells with positive staining of
cleaved caspase-3 were counted from three randomly selected areas
(a total of 360 tumor cells were counted for each area) in each slide. The
three areas were first identified by scanning the entire slide at ×10
magnification, and then the positive staining cells were counted at ×20
magnification using an Olympus B×40 Microscope. The bar graphs show
the percentage of cells with positive staining for cleaved caspase-3 from
each group. The combinatorial treated mice had significantly higher
proportion of cells stained positive for cleaved caspase-3 than the
control mice or single Ab treated mice, P < 0.002.Abbreviations
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